Literature DB >> 25421512

Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging.

Karl Mann1, Sabine Vollstädt-Klein, Iris Reinhard, Tagrid Leménager, Mira Fauth-Bühler, Derik Hermann, Sabine Hoffmann, Ulrich S Zimmermann, Falk Kiefer, Andreas Heinz, Michael N Smolka.   

Abstract

BACKGROUND: Effect sizes of pharmacotherapy in alcoholism are modest. They might improve if subjects could be divided into more homogeneous subgroups and would then be treated targeted to their neurobiological profile. In such an effort, we tested neural cue reactivity as a potential predictor of treatment response to naltrexone. Alcohol-associated cues cause brain activations in mesocorticolimbic networks due to the positive reinforcing properties of alcohol. These activations were reported to be associated with relapse behavior. Naltrexone, an antagonist at the mu-opioid receptor, improves drinking behavior in some but not all patients probably by blocking the positive reinforcement of alcohol. Conversely, acamprosate is proposed to modulate negative reinforcement (withdrawal and cue-induced withdrawal). Identifying subjects with elevated cue reactivity and testing their response to medical treatment could thus improve our understanding of some of the mechanisms underlying pharmacotherapy response.
METHODS: A picture-perception task featuring alcohol-related and neutral stimuli was presented to 64 recently detoxified alcohol-dependent patients. Patients came from 1 center of a larger double-blind randomized multicenter clinical trial (the "PREDICT Study"). They were scanned prior to being randomized to either naltrexone or acamprosate. We examined the interaction between medication and functional magnetic resonance imaging (fMRI) cue reactivity, as measured by the percentage of voxels activated, using the time to the first severe relapse as the outcome criterion. Our a priori formulated hypothesis was that naltrexone but not acamprosate should be efficacious in subjects with high cue reactivity.
RESULTS: We observed an interaction effect between pretreatment brain activation induced by alcohol images and medication (acamprosate/naltrexone) on relapse behavior. In line with our hypothesis, this interaction was driven by treatment response to naltrexone in patients with elevated pretreatment cue reactivity in the ventral striatum.
CONCLUSIONS: fMRI has the potential for predicting treatment response to naltrexone in a subgroup of alcohol-dependent patients. However, this approach will be limited to researching the mechanisms and principles of treatment response.
Copyright © 2014 by the Research Society on Alcoholism.

Entities:  

Keywords:  Acamprosate; Alcohol; Cue Reactivity; Naltrexone; Personalized Medicine; Relapse; fMRI

Mesh:

Substances:

Year:  2014        PMID: 25421512     DOI: 10.1111/acer.12546

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  39 in total

1.  Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.

Authors:  Joseph P Schacht; Patrick K Randall; Patricia K Latham; Konstantin E Voronin; Sarah W Book; Hugh Myrick; Raymond F Anton
Journal:  Neuropsychopharmacology       Date:  2017-04-14       Impact factor: 7.853

2.  Response to Letter to Editor (Precision medicine in alcohol dependence: evidence of efficacy and initial support for comparative effectiveness).

Authors:  Karl Mann; Corey R Roos; Katie Witkiewitz
Journal:  Neuropsychopharmacology       Date:  2018-06-12       Impact factor: 7.853

3.  Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline.

Authors:  Robert Miranda; Stephanie S O'Malley; Hayley Treloar Padovano; Ran Wu; Daniel E Falk; Megan L Ryan; Joanne B Fertig; Thomas H Chun; Srinivas B Muvvala; Raye Z Litten
Journal:  Alcohol Clin Exp Res       Date:  2020-05-25       Impact factor: 3.455

4.  A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder.

Authors:  Milky Kohno; Laura E Dennis; Holly McCready; Daniel L Schwartz; William F Hoffman; P Todd Korthuis
Journal:  Drug Alcohol Depend       Date:  2018-09-21       Impact factor: 4.492

5.  The importance of standardization of stimuli for functional MRI tasks to evaluate substance use disorder pathology.

Authors:  Claire E Wilcox; Eric D Claus
Journal:  Am J Drug Alcohol Abuse       Date:  2017-03-27       Impact factor: 3.829

Review 6.  Neuroimaging the Effectiveness of Substance Use Disorder Treatments.

Authors:  Elizabeth A Cabrera; Corinde E Wiers; Elsa Lindgren; Gregg Miller; Nora D Volkow; Gene-Jack Wang
Journal:  J Neuroimmune Pharmacol       Date:  2016-05-16       Impact factor: 4.147

7.  [Pharmacological prophylactic treatment for relapse of alcohol dependence : Results of current meta-analyses].

Authors:  J Mutschler; M Soyka
Journal:  Nervenarzt       Date:  2017-03       Impact factor: 1.214

8.  Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.

Authors:  Corey R Roos; Karl Mann; Katie Witkiewitz
Journal:  Addict Biol       Date:  2016-08-02       Impact factor: 4.280

Review 9.  Neural substrates of cue reactivity: association with treatment outcomes and relapse.

Authors:  Kelly E Courtney; Joseph P Schacht; Kent Hutchison; Daniel J O Roche; Lara A Ray
Journal:  Addict Biol       Date:  2015-10-04       Impact factor: 4.280

10.  Neurofunctional Domains Derived From Deep Behavioral Phenotyping in Alcohol Use Disorder.

Authors:  Laura E Kwako; Melanie L Schwandt; Vijay A Ramchandani; Nancy Diazgranados; George F Koob; Nora D Volkow; Carlos Blanco; David Goldman
Journal:  Am J Psychiatry       Date:  2019-01-04       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.